Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of the study is to determine a) if the implementation of belatacept patient alert card (PAC) resulted in effective understanding of key safety messages and b) if the degree of understanding of key safety messages is associated with improved clinical and safety outcomes.
3 sub studies: 2 Cross-Sectional and 1 retrospective chart review
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Patients survey | Adult patients treated with belatacept for renal transplantation | ||
| HCP survey | HCP with at least 1 patient taking belatacept | ||
| Retrospective chart review study | Adult patients treated with belatacept for renal transplantation |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Patient survey: Proportion of patients treated with belatacept who are aware of the existence of the PAC | At patient enrolment | |
| Patient survey : Proportion of patients treated with belatacept who have received the PAC | At patient enrolment | |
| Patient survey : Proportion of patients who have utilised the PAC, and the extent of its use | At patient enrolment | |
| Patient survey: Levels of patient knowledge and comprehension related to the important identified risks of belatacept treatment | At patient enrolment | |
| Patient survey: HCP-patient communication based on responses to specific questions | At patient enrolment | |
| Patient survey: Proportion of patients with correct responses to behavioral questions | At patient enrolment | |
| Patient survey: Mean scores for correct responses for questions grouped by objectives | Objectives: distribution, awareness, utility, utilization and knowledge | At patient enrolment |
| HCP survey: Proportion of HCPs who prescribe or administer belatacept in nephrology centres who are aware of the PAC | Day 1 | |
| HCP survey: Proportion of HCPs who have utilised the PAC, and the extent of its use |
| Measure | Description | Time Frame |
|---|---|---|
| Major determinants of patients knowledge of the key messages contained in the belatacept PAC based on data collected in the patient questionnaire | Determinants: Age, gender, educational level, number of prescription medications, duration of therapy with belatacept | At patient enrolment |
| Major determinants of understanding the key messages contained in the PAC based on data collected in the patient questionnaire |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Cohort 1: Patient enrolled by physicians based in hospital and physician renal units
Cohort 2: Physicians and nurses based in hospital and physician renal units
Cohort 3: Patient enrolled by physicians based in hospital and physician renal units
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Bristol-Myers Squibb | Bristol-Myers Squibb | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Local Institution | Linz | A-4020 | Austria | |||
| Local Institution |
Not provided
Not provided
Not provided
Not provided
| Day 1 |
| HCP survey: Levels of HCPs' knowledge and comprehension related to the important identified risks of infections and the need to screen for specific infection prior to initiating or administering belatacept | The percentage of HCPs with responses to each question in the HCP questionnaire that would indicate effectiveness of the PAC will be determined: who are aware of the PAC, use the PAC, level of knowledge and comprehension of the risks and mean scores for correct responses | Day 1 |
| HCP survey: Behavior of HCPs based on responses to behavioral questions | Day 1 |
| HCP survey: Mean total score for correct responses | Day 1 |
| HCP survey: Mean scores for correct responses for questions grouped by objectives | Objectives: distribution, awareness, utility, utilization and knowledge | Day 1 |
| Retrospective chart review study (clinical outcome study): Proportion of serious infections | Upto 4 years |
Determinants: Age, gender, educational level, number of prescription medications, duration of therapy with belatacept |
| At patient enrolment |
| Major determinants of implementation regarding the key messages contained in the PAC based on data collected in the patient questionnaire | Determinants: Age, gender, educational level, number of prescription medications, duration of therapy with belatacept | At patient enrolment |
| Determinants of Health Care Professional (HCP) understanding and implementation regarding key messages contained in the PAC based on data collected in the patient questionnaire | Determinants: type of HCP, country, age and gender of HCP years in specialty, number of HCPs in the unit, annual number of patients through the unit, number of patients for whom belatacept was prescribed in the previous 12 months, type of practice, type of institution (academic or non-academic), size of town | Day 1 |
| Retrospective chart review study (clinical outcome study) : proportion of infections leading to discontinuation | Upto 4 years |
| Retrospective chart review study (clinical outcome study) : mean time from symptom onset of infection to receipt of medical therapy | Upto 4 years |
| Retrospective chart review study (clinical outcome study) : Mean time to diagnosis of graft rejection by biopsy criteria | Upto 4 years |
| Vienna |
| A-1090 |
| Austria |
| Local Institution | Besançon | 25030 | France |
| CHU Brest Hopital La Cavale Blanche | Brest | 29200 | France |
| CHU Bordeaux Hopital Pellegrin | Burdeux | 33000 | France |
| CHU Clemont Ferrand | Clermont-Ferrand | 63000 | France |
| APHP Hopital Henri Mondor | Créteil | 94000 | France |
| Local Institution | Le Kremlin-Bicêtre | 94270 | France |
| CHU Toulouse Hopital Rangueli | Toulouse | 31059 | France |
| CHU Tours Hopital Bretonneau | Tours | 37000 | France |
| Local Institution | Dresden | 1307 | Germany |
| Local Institution | Kiel | 24105 | Germany |
| UK Mannheim | Mannheim | 68167 | Germany |
| Local Institution | Uppsala | 75185 | Sweden |